Oncotelic Therapeutics, Inc. (OTLC)

OTCMKTS: OTLC · Delayed Price · USD
0.0354
-0.0006 (-1.64%)
Mar 28, 2024, 3:10 PM EDT - Market open

Company Description

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications.

The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.

It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies.

Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Oncotelic Therapeutics, Inc.
Country Canada
IPO Date Aug 26, 1993
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Dr. Vuong Trieu Ph.D.

Contact Details

Address:
29397 Agoura Rd., #107
Aguora Hills, California 91301
United States
Phone 650-635-7000
Website oncotelic.com

Stock Details

Ticker Symbol OTLC
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000908259
CUSIP Number 628341109
ISIN Number US6283411097
Employer ID 13-3679168
SIC Code 2834

Key Executives

Name Position
Dr. Vuong Trieu Ph.D. Chairman and Chief Executive Officer
Amit Shah Chief Financial Officer
Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. Chief Clinical Officer of Translational Medicine and Director
Saranjit Saund CBO and GM of AI Division
Steven W. King Consultant and Director
Dr. Larn Hwang Chief Scientific Officer
Dr. Seymour Howard Fein M.D. Chief Medical Officer
Burcak Beser Chief Technology Officer of AI Division

Latest SEC Filings

Date Type Title
Feb 2, 2024 8-K Current Report
Nov 14, 2023 10-Q Quarterly Report
Oct 30, 2023 8-K Current Report
Aug 23, 2023 8-K Current Report
Aug 18, 2023 10-Q Quarterly Report
Aug 15, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Jul 13, 2023 D Notice of Exempt Offering of Securities
Jul 13, 2023 8-K Current Report
May 22, 2023 10-Q Quarterly Report
May 19, 2023 8-K Current Report